100 related articles for article (PubMed ID: 1771298)
21. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
22. Bepridil enhances adriamycin-induced DNA biosynthesis inhibition in human myeloid leukemia cells.
Parekh H; Advani S; Chitnis M
Sel Cancer Ther; 1990; 6(4):183-91. PubMed ID: 2094938
[TBL] [Abstract][Full Text] [Related]
23. Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro.
Li L; You LS; Mao LP; Jin SH; Chen XH; Qian WB
Acta Pharmacol Sin; 2018 Feb; 39(2):251-260. PubMed ID: 28905936
[TBL] [Abstract][Full Text] [Related]
24. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
25. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
26. Effect of pentoxifylline on P-glycoprotein mediated vincristine resistance of L1210 mouse leukemic cell line.
Breier A; Barancík M; Stefanková Z; Uhrík B; Tribulová N
Neoplasma; 1994; 41(5):297-303. PubMed ID: 7854500
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines.
Almeida TP; Ferreira J; Vettorazzi A; Azqueta A; Rocha E; Ramos AA
Environ Toxicol Pharmacol; 2018 Apr; 59():24-33. PubMed ID: 29518678
[TBL] [Abstract][Full Text] [Related]
28. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
Cai H; Li L; Jiang J; Zhao C; Yang C
Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974
[TBL] [Abstract][Full Text] [Related]
29. Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist.
Parekh HK; Shallom JM; Advani SH; Chitnis MP
Neoplasma; 1991; 38(6):575-81. PubMed ID: 1766484
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
31. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
32. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
33. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
34. [In vitro induction of apoptosis in acute myelogenous and lymphoblastic leukemia cells by adriamycine is increased by pentoxifylline].
Hernández-Flores G; Bravo-Cuellar A; Aguilar-Luna JC; Lerma-Díaz JM; Barba-Barajas M; Orbach-Arbouys S
Presse Med; 2010 Dec; 39(12):1330-1. PubMed ID: 20888731
[No Abstract] [Full Text] [Related]
35. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
36. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
38. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
39. Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells.
Goel PN; Gude RP
Biomed Pharmacother; 2014 Mar; 68(2):191-200. PubMed ID: 24373697
[TBL] [Abstract][Full Text] [Related]
40. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
